ABSTRACT
Viral hepatitis with the major hepatotropic agents (hepatitis A-D) and their serological markers are common in Human Immunodeficiency Virus (HIV) seropositive individuals and patients with the Acquired Immune Deficiency Syndrome (AIDS), reflecting shared risk factors such as sexual promiscuity, intravenous drug use (IVDU) and multiple transfusions. Management issues surrounding chronic hepatitis B and C, including treatment options and side-effects of anti-viral therapies, have become important subsequent to the improved survival of patients with HIV infection and AIDS.
